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A B S T R A C T
Hyperlipidemia is a major cause of cardiovascular disease despite the availability of 
first-line cholesterol lowering agents such as statins. Although statin therapy is very ef-
ficient to reduce cholesterol, nearly 10-20% of individuals on statins, experience side 
effects, such myopathy, which hinder the drugs ability to achieve target low-density 
lipoprotein (LDL) cholesterol (LDL-C) levels. Statin-intolerant patients require more 
effective therapies for lowering LDL-C.
As proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation 
of the LDL receptor (LDLR) and prevents it from recycling to the membrane, a new 
therapeutic approach to lowering LDL-C acts by blocking LDL-receptor degradation 
by serum PCSK9. Humanized monoclonal antibodies which target PCSK9 and its 
interaction with the LDL receptor (REGN727/SAR23653, AMG145, and RN316), as 
well as agents that inhibit PCSK9 synthesis, such as ALN-PCS, are now in clinical tri-
als. The latter is a small interfering RNA (siRNA) that directs sequence-specific mes-
senger RNA for PCSK9 leading to reduced hepatocyte-specific synthesis of PCSK9. 
Ongoing phase III trials’ results are awaited with great interest in order to define 
these agents’ long-term safety, tolerability and efficacy for reducing cardiovascular 
events.
I n T R o d u C T I o n
Hypercholesterolemia, particularly high concentration of low-density lipoprotein 
(LDL) cholesterol (LDL-C), is associated with atherosclerotic vascular disease and 
adverse events including myocardial infarction, cerebrovascular accidents and tran-
sient ischemic attacks and is a leading contributor to cardiovascular-related morbidity 
and mortality around the world.1,2 Statin therapy has been shown to reduce LDL-C 
levels by up to 63% from baseline and is the first-line pharmacologic treatment for 
hypercholesterolemia.3 Although statin therapy is very efficient to reduce cholesterol, 
nearly 10-20% of individuals on statins experience side effects, such as myopathy, which 
hinder the drugs ability to achieve target LDL levels.4 Moreover, single nucleotide 
polymorphisms have been reported to be linked to resistance to statin therapy.5 As 
a result of these goal-limiting factors, there is an ongoing search for new, non-statin 
cholesterol lowering agents, such as PCSK9 inhibitors.
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AbbreviAtions
ADH = autosomal dominant 
hypercholesterolemia 
CHD = coronary heart disease 
FH = familial hypercholesterolemia 
GOF = gain-of-function 
LDL = low-density lipoprotein
LDL-C = low-density lipoprotein 
cholesterol
LDLR = LDL receptor
LOF = loss-of-function
PCSK9 = proprotein convertase subtilisin/
kexin type 9 
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T H E  d I S C o V E R Y  o f  P S C K 9
In 2003, Seidah et al identified the ninth member of the 
proprotein convertase family, PCSK9.6 The human PCSK9 
gene located on chromosome 1p32.3 encodes a 692-amino 
acid inactive glycoprotein. PCSK9 is expressed in several 
organs, particularly the liver and also the intestine, intestinal 
ileum, and colon epithelia and the kidney.7 Shortly after that, 
the identification of two gain-of-function (GOF) mutations 
in PCSK9, in two French families with a clinical diagnosis of 
autosomal dominant hypercholesterolemia (ADH) and no 
detectable mutations in LDL receptor (LDLR) or apoB100 
genes, made evident the involvement of PCSK9 in regulating 
cholesterol metabolism.8 Several other GOF mutations have 
been reported,9 associated with mild to severe hypercholester-
olemia and increased risk of coronary heart disease (CHD).10 
Conversely, loss-of-function (LOF) mutations associated with 
PCSK9 inhibition probably has a role in decreasing LDL-C 
concentration. 
R o l E  o f  P C S K 9 
Low-density lipoprotein (LDL) particles are removed 
from the circulation mainly by hepatic uptake via the LDL 
receptor (LDLR). LDL binds to the LDLR and the LDL/
LDLR complex is internalized into clathrin-coated vesicles by 
endocytosis. Then, LDL is separated from its receptor in the 
endosomes and the LDLR is recycled for reuse. At the same 
time, LDL is degraded.
The plasma concentration of LDL-C is regulated by both 
environmental and genetic factors. In the majority of the 
cases, familial hypercholesterolemia (FH) is related to muta-
tions in the LDLR itself, and less frequently to mutations in 
the ligand-binding domain of apolipoprotein (apo)B100, the 
protein component of LDL that interacts with the LDLR.11 The 
third gene associated with FH, is related to mutations encoding 
proprotein convertase subtilisin/kexin type 9 (PCSK9) which 
plays a central role in regulation of cholesterol homeostasis 
by enhancing the endosomal and lysosomal degradation of 
hepatic LDLR, resulting in decreased extraction of LDL-C 
from the circulation and in increased serum LDL-C con-
centrations.12,13 Furthermore, PCSK9 shortens the half-life 
of LDLR,14 a process independent of its catalytic activity.1 
In a subsequent study, real-time PCR analysis showed that 
increased cholesterol consumption by mice was associated 
with down –regulation of PCSK9 rnRNA.16 As expected, the 
presence of mevalonate, a product of HMG-CoA reductase 
on HMG-CoA, was found to down-regulate PCSK9 mRNA 
transcription, and conversely, expression of PCSK9 rnRNA is 
up-regulated by HMG-CoA reductase inhibitors.15,17 
Gain-of-function mutations in the PCSK9 gene lead 
to autosomal dominant hypercholesterolemia (ADH),8 as 
do mutations in the LDLR and APOB genes. Conversely, 
loss-of-function mutations (LOF) of the PCSK9 gene were 
discovered and linked to low plasma LDL-C levels and a 
reduction of cardiovascular risk.18,19 The first LOF mutations 
were described in 2005 18 and the effect of lifelong reductions 
in LDL-C induced by these LOF mutations was examined in 
the atherosclerosis risk in communities study.19 LOF mutations 
Y142X and C679X in African Americans were associated with 
a 28% reduction in LDL-C and an 88% reduction in the risk of 
CHD, whereas the R46L mutation in Caucasians was associ-
ated with a 15% reduction in LDL-C and a 47% reduction in 
the risk of CHD.19 Since PCSK9 is a key regulator for LDLR 
activity, the PCSK9 inhibition seems an attractive target for 
the treatment of hypercholesterolemia.8-10
P H A R m A C o l o g I C A l  S T R A T E g I E S 
T A R g E T I n g  P C S K 9
So far, several therapeutic strategies have been developed 
in order to reduce circulating PCSK9 (Table 1). Small-mole-
cule inhibitors of PCSK9 seem to be hard to design and their 
development has not reached the safety and efficacy stages in 
preclinical studies, therefore these compounds are not cur-
rently included in therapeutic options.
More successful is the gene-silencing approach. PCSK9 
can be inhibited by single-stranded antisense DNA-like 
oligonucleotides or by double-stranded small interference 
RNA. These treatments successfully increase hepatic LDLR 
and lower plasma LDL-C in animal models. However, two 
antisense nucleotides directed at reducing PCSK9 in humans 
have recently discontinued development. Another approach 
which has been tested is the PCSK9 peptide sequences which 
are too short to promote LDLR degradation but long enough 
to compete with full-length PCSK9. Despite the merits of 
these approaches, fully human monoclonal antibodies (mAbs) 
targeting PCSK9 currently appear to lead the way with the pub-
lication in 2012 of the results from phase I and II clinical trials. 
Three major pharmaceutical teams, Sanofi US (Bridge-
water, NJ)/Regeneron Inc. (Tarrytown, NY), Amgen Inc. 
TABlE 1.
Investigational approaches targeting PCSK9
Agents that inhibit binding of PCSK9 to the LDL receptor (e.g. 
monoclonal antibody therapy)
Agents that inhibit PCSK9 synthesis (e.g. small interfering RNA, 
antisense oligonucleotides)
Potentially, agents that inhibit intracellular processing of PCSK9
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(Thousand Oaks, CA), and Pfizer Inc. (New York, NY) have 
invested extensive research efforts into exploring the potential 
of blocking LDL-receptor degradation by serum proprotein 
convertase subtilisin kexin 9 (PCSK9) 20 via the humanized 
monoclonal antibodies designated REGN727/SAR236553 
or alirocumab (subcutaneous administration), AMG 145 or 
evolocumab (subcutaneous administration), and RN316 or 
bococizumab (intravenous administration) respectively.
In healthy individuals, the Sanofi-Aventis/ Regeneron 
SAR236553/REGN727 antibody reduced LDL-C by 33–46%, 
in a dose dependent fashion, when administered subcuta-
neously.21 On top of atorvastatin, in hypercholesterolemic 
individuals, multiple doses of the Sanofi compound reduced 
cholesterol levels by 41–58% in patients with familial hyper-
cholesterolemia and by 38–65% in nonfamilial hypercholes-
terolemia. In a phase II study of patients on a stable dose of 
atorvastatin (10–40 mg/day), with LDL-C levels at least 100 
mg/dl ,the administration of SAR236553/REGN727 antibody 
every 2 weeks resulted in LDL-C reductions of 40–72%.22 In 
heterozygous familial hypercholesterolemia patients at high 
cardiovascular risk treated with high to maximal doses of 
statins with or without ezetimibe, the SAR236553/REGN727 
antibody, every 2 weeks, reduced LDL-C by up to 68%.23 In 
another study conducted in patients on low-dose atorvas-
tatin (10 mg/day) with LDL-C levels at least 100 mg/dl, the 
co-administration of 150 mg of the SAR236553/REGN727 
antibody every 2 weeks resulted in 66% reduction of LDL-C, 
whereas an up-titration of atorvastatin, to the maximal dose 
(80 mg/day) lowered LDL-C by 17%.24
On the other hand, in healthy individuals, the Amgen an-
tibody AMG145 dose-dependently decreased LDL-C by up to 
64% in comparison to placebo when injected subcutaneously.25 
In patients on stable doses of statins, the administration of 
AMG145 reduced LDL-C by up to 75%. In familial hyper-
cholesterolemic patients on statins with or without ezetimibe, 
AMG145 dose-dependently decreased LDL-C levels by up to 
55%.26 The Amgen antibody reduced LDL-C by up to 51% in 
statin-intolerant dyslipidemic patients.27 Administration of 140 
mg of the AMG145 antibody every 2 weeks reduced LDL-C by 
51% in monotherapy, in patients with hypercholesterolemia,28 
and by 66% on top-of-statin treatment vs. placebo.29
Thus, similar doses (140–150 mg) of either SAR236553/
REGN727 or AMG145 mAbs infused every 2 weeks appear to 
display similar efficacies in terms of LDL-C reduction, whether 
in monotherapy, or on top-of-statin treatment. Noteworthy, 
both compounds reduced LDL-C down to optimal target lev-
els (≤70 mg/dl) in the vast majority of heterozygous familial 
hypercholesterolemia patients enrolled in those studies,23,26 
suggesting that PCSK9 inhibition will be athero-protective in 
familial hypercholesterolemia, as indicated by the positive cor-
relation that exists between elevated plasma PCSK9 levels and 
the severity of the familial hypercholesterolemia phenotype.30 
RN316, from Pfizer Inc, unlike the other two human 
monoclonal antibodies is administered intravenously. Gum-
biner et al, in a phase II clinical trial, evaluated the efficacy 
and safety of RN316 in participants with hypercholesterolemia 
on concurrent high dose statin therapy.31 Participants in the 
first arm of this trial (n=90) had LDL-C ≥100 mg/dl and were 
given either the study drug or placebo while on concurrent 
high doses of atorvastatin (40 or 80 mg), rosuvastatin (20 or 
40 mg), or simvastatin (40 or 80 mg). The second arm (n=45) 
included participants with LDL-C ≥80 mg/dl given study drug 
or placebo while on atorvastatin 80 mg or rosuvastatin 40 mg. 
After 12 weeks, pooled results from both arms showed a 56% 
reduction in LDL-C in the study drug group as compared 
with a 4% reduction in the placebo group. It is possible that 
an even greater reduction in the study drug group may have 
been achieved, since dosing was interrupted at week 4 due to 
LDL-C dropping below 25 mg/dl in several patients. No study 
drug related adverse events were reported, and RN316 was 
well tolerated.31 
Another therapeutic option available is the use of agents 
that inhibit PCSK9 synthesis, such as ALN-PCS. This is a 
small interfering RNA (siRNA) that directs sequence-specific 
messenger RNA for PCSK9 leading to reduced hepatocyte-
specific synthesis of PCSK9.32 A recent placebo-controlled 
phase I study of healthy individuals with hypercholesterolemia 
showed that ALN-PCS achieved 40% reduction in LDL-C 
levels, whereas adverse event proportions were similar in the 
treatment and placebo groups. No significant increase of liver 
function enzymes or inflammatory markers was reported.33 
C o n C l u S I o n S
A significant proportion of high risk patients fail to achieve 
LDL-C goals recommended by guidelines, despite the intense 
treatment with currently available lipid lowering agents. Re-
duction of LDL-C levels through PCSK9 inhibition seems to be 
a new attractive therapeutic approach. Monoclonal antibodies, 
such as AMG145 and SAR236553/REGN727, currently ap-
pear to lead the way in targeting PCSK9 and to enable most 
patients at highest risk for adverse cardiovascular events to 
achieve the most stringent recommended lipid goals. Phase III 
trials with larger patient populations and over longer periods 
are currently underway. The results of these trials are awaited 
with great interest in order to define these agents’ long-term 
safety, tolerability and efficacy for reducing cardiovascular 
events in humans. 
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